MIIT issues proposed Medical Equipment Industry Development Plan for 2021-2025



The Ministry of Industry and Information Technology (MIIT) released the “2021-2025 Medical Equipment Industry Development Plan” (draft proposal), soliciting public feedback until March 11. During the 13th Five-Year Plan period (2016-2020), the medial equipment market grew at a 13.6% compound annual growth rate and reached RMB 80 billion (USD 12.3 billion) in market value in 2019. International sales accounted for over 10% of domestic production.

MIIT's document sets out goals to be achieved by 2025, including: major breakthroughs in key components and materials, safe and reliable high-end medical equipment, world-class product performance and quality, a basically complete medical equipment industry system, and 6-8 companies ranked among the top 50 global medical equipment firms.

The plan highlights diagnostic testing, treatment, monitoring and life support, traditional Chinese medicine diagnosis and treatment, maternal and child health, health care and rehabilitation, and implant intervention sectors. Cross-border integration and innovation will be reinforced, where medical equipment and electronic information, communication network, Internet and more will be supported for cooperation, and conventional medical equipment will be integrated with 5G, artificial intelligence, industrial internet, cloud computing, 3D printing, and other new technologies for upgrade.

The aerospace, nuclear, new materials, and other industries will cooperate with the medical equipment industry, where materials, components, complete machines, and other upstream and downstream industrial chains will see coordinated development. In addition, government procurement management will be ramped up with a fair, open, and fully competitive medical equipment procurement mechanism to be established, and a government industrial financing model to be explored.

Reference:

Recent news
Brazil’s Ministry of Health (MoH) last week signed a contract with local pharmaceutical company Precisa Medicamentos for the purchase of 20 million doses of Indian partner Bharat Biotech’s SARS-CoV-2 vaccine Covaxin, totalling BRL 1.6 billion (USD 288 million).
Argentina’s Ministry of Health (MoH) last week launched two direct drug purchases aimed at procuring contraceptives from Bayer.
Mexico-based pharmaceutical firm Genomma Lab last week released 2020 financials, reporting MXN 13.9 billion (USD 670 million) turnover after 9.1% year-on-year (YOY) growth, and flaunting minor negative impact of the COVID-19 pandemic.
  • 1614588392046
  • Argentina,Brazil,Colombia,Chile,Puerto Rico ,Costa Rica,Panama,Peru,Paraguay,Uruguay,Ecuador ,Bolivia ,Mexico,Guatemala,Honduras,El Salvador,Belize,Nicaragua
  • Company
Argentine pharmaceutical company Richmond last week signed a memorandum of understanding (MoU) with the Russian Direct Investment Fund (RDIF) for the local manufacturing of the latter’s SARS-CoV-2 vaccine Sputnik V, which was rolled out in the country in December last year.
China's Center for Drug Evaluation (CDE) website indicates that FutureGen Biopharma’s M108, a claudin 18.2 (CLDN18.2) targeted monoclonal antibody (mAb), has passed the clinical trial approval process and will be assessed in general advanced solid tumors.
German giant Bayer HealthCare entered into a memorandum of understanding with the China Alliance of Rare Diseases (CARD).
Beijing-based DaWei Biotechnology, a microfluidic technology driven molecular diagnostics specialist, struck a partnership with leading domestic in vitro diagnostics company Maccura Biotechnology Co., Ltd (300463.SZ) on next-generation molecular diagnostics technologies.
Analytics Snapshot


Analytics Snapshot